Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69945-0177-01 69945-0177 LUTETIUM OXODOTREOTIDE LU-177 BEXLUTRY 10.0 mCi/mL Radiopharmaceutical Somatostatin Analog SSTR2 Intravenous Sep 14, 2026 In Use
69488-0010-61 69488-0010 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 27.0 mCi/mL Radiopharmaceutical Radiopharmaceutical PSMA Intravenous Mar 23, 2022 In Use
00078-1217-61 00078-1217 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 27.0 mCi/mL Radiopharmaceutical Radiopharmaceutical PSMA Intravenous Jan 15, 2026 In Use
00007-3261-01 00007-3261 Tositumomab, Iodine I-131 Bexxar Dosimetric Immunotherapy Radioimmunotherapy CD20 Jul 15, 2009 Feb 13, 2014 No Longer Used
69097-0038-07 69097-0038 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Aug 30, 2026 In Use
31722-0770-32 31722-0770 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
00781-2358-27 00781-2358 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 1, 2026 In Use
78206-0195-01 78206-0195 Denosumab Bilprevda 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Sep 11, 2025 In Use
00003-4522-11 00003-4522 Elotuzumab Empliciti 400.0 mg/1 Immunotherapy Monoclonal Antibody SLAMF7 Intravenous Nov 30, 2015 In Use
83616-0106-11 83616-0106 Vusolimogene oderparepvec-wtpg Tudriqev 1000000.0 [PFU]/mL Immunotherapy Oncolytic Viral Therapy GALV-GP-R, GM-CSF INTRATUMOR Sep 4, 2026 In Use
69097-0036-07 69097-0036 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Aug 30, 2026 In Use
69097-0036-81 69097-0036 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Aug 30, 2026 In Use
69097-0039-07 69097-0039 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Aug 30, 2026 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec 18, 2019 In Use
61755-0054-01 61755-0054 Linvoseltamab-gcpt LYNOZYFIC 5.0 mg/2.5mL Immunotherapy Monoclonal Antibody BCMA, CD3 Intravenous Jul 2, 2025 In Use
57894-0502-20 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Nov 30, 2024 In Use
78206-0148-01 78206-0148 Ontruzant Ontruzant Immunotherapy Monoclonal Antibody HER2 Intravenous Jun 1, 2021 In Use
73042-0201-01 73042-0201 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Nov 25, 2020 In Use
57894-0502-05 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Oct 31, 2024 In Use
70377-0054-11 70377-0054 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 3, 2025 In Use
00004-0357-99 00004-0357 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Aug 22, 2011 Sep 19, 2014 No Longer Used
61755-0056-01 61755-0056 Linvoseltamab-gcpt LYNOZYFIC 200.0 mg/10mL Immunotherapy Monoclonal Antibody BCMA, CD3 Intravenous Jul 2, 2025 In Use
50633-0230-01 50633-0230 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Sep 1, 2026 In Use
16729-0692-09 16729-0692 Lenalidomide Lenalidomide 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Apr 8, 2026 In Use
00006-5083-01 00006-5083 Pembrolizumab and berahyaluronidase alfa-pmph KEYTRUDA QLEX 2000.0 U/mL, 165.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Sep 19, 2025 In Use

Found 12611 results — Export these results